Company: HRTX
Filing Date: 2025-10-29
Form Type: 8-K
Source: 0001193125-25-256300
Chunk: 0

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-10-29
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 27, 2025, the Board of Directors (the “ Board”) of Heron Therapeutics, Inc. (the “ Company”) appointed Thomas Cusack to the Board to serve for a term expiring at the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal. In connection with his appointment, Mr. Cusack will be appointed to the Nominating and Corporate Governance Committee of the Board. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025.

There were no arrangements or understanding between Mr. Cusack and any other person pursuant to which he was appointed as a director of the Company. Mr. Cusack does not have a direct or indirect material interest in any transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K.

For his service as a non-employee director of the Company, Mr. Cusack will receive compensation in accordance with the Company’s standard compensation program for its non-employee directors, which is described under the heading “ Non-Employee Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 30, 2025. In addition, Mr. Cusack will enter into the Company’s standard form of Director Indemnification Agreement (the “ Indemnification Agreement”).

The foregoing description of the Indemnification Agreement does not purport to be complete and is subject to, and qualified in its entirety by the full text of the form of Indemnification Agreement, which will be filed as an exhibit with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.